1. Clinical & Scientific Overview
Baclofen & Tizanidine Hydrochloride (TIP-MED-000128, Reference Code [7.26]) is classified under
Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a GABA-B Receptor Agonist & Central Alpha-2 Adrenoceptor Agonist Antispasticity Agents (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.26], p. 91): Baclofen: Liofen / Liofen XL (Sun), Riclofen. Tizanidine: Sirdalud (Novartis), Tizan (Sun); FDCs with Aceclofenac/Nimesulide — Strengths & Dosage Forms: Baclofen Tablets: 5 mg, 10 mg, 20 mg; XL Capsules: 10 mg, 20 mg, 30 mg. Tizanidine Tablets: 2 mg, 4 mg
Baclofen Tablets: 5 mg, 10 mg, 20 mg; XL Capsules: 10 mg, 20 mg, 30 mg. Tizanidine Tablets: 2 mg, 4 mg
3. Mechanism of Action & Pharmacodynamics
GABA-B Receptor Agonist & Central Alpha-2 Adrenoceptor Agonist Antispasticity Agents (Schedule H) acting on target receptor/enzyme pathways in Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07): clinical efficacy is mediated via GABA-B Receptor Agonist & Central Alpha-2 Adrenoceptor Agonist Antispasticity Agents (Schedule H) for Spasticity, flexor spasms, and clonus resulting from multiple sclerosis, spinal cord injury, stroke, or cerebral palsy.
4. Therapeutic Indications & Evidence-Supported Uses
- Spasticity, flexor spasms, and clonus resulting from multiple sclerosis, spinal cord injury, stroke, or cerebral palsy
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Baclofen: Start 5 mg PO TDS for 3 days, increase by 5 mg/dose every 3 days to 10–20 mg TDS (Max 80 mg/day). Tizanidine: Start 2 mg PO at bedtime or TDS, titrate to 4 mg TDS (Max 24–36 mg/day)
Administration & Meal Timing: Take Baclofen WITH food or milk to prevent nausea; take Tizanidine consistently either always with or always without food | Three times daily (or largest dose at bedtime for nocturnal flexor spasms)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: CRITICAL BACLOFEN RENAL WARNING: Baclofen is 85% excreted unchanged by the kidney — CONTRAINDICATED in eGFR <30 mL/min and dialysis (even 1–2 tablets of Baclofen 10 mg in dialysis patients cause acute coma and respiratory arrest!). Tizanidine: Halve dose if CrCl <25 mL/min. Hepatic: Avoid Tizanidine in liver disease
Renal: CRITICAL BACLOFEN RENAL WARNING: Baclofen is 85% excreted unchanged by the kidney — CONTRAINDICATED in eGFR <30 mL/min and dialysis (even 1–2 tablets of Baclofen 10 mg in dialysis patients cause acute coma and respiratory arrest!). Tizanidine: Halve dose if CrCl <25 mL/min. Hepatic: Avoid Tizanidine in liver disease
Renal: CRITICAL BACLOFEN RENAL WARNING: Baclofen is 85% excreted unchanged by the kidney — CONTRAINDICATED in eGFR <30 mL/min and dialysis (even 1–2 tablets of Baclofen 10 mg in dialysis patients cause acute coma and respiratory arrest!). Tizanidine: Halve dose if CrCl <25 mL/min. Hepatic: Avoid Tizanidine in liver disease
7. Contraindications, Precautions & High-Risk Warnings
- LIFE-THREATENING BACLOFEN WITHDRAWAL SYNDROME: Abrupt discontinuation of chronic Baclofen precipitates hyperthermia, hallucinations, delirium, rebound spasticity, rhabdomyolysis, status epilepticus, and multi-organ failure — always taper over >=1–2 weeks! Tizanidine is STRICTLY CONTRAINDICATED with Ciprofloxacin and Fluvoxamine!
Key Clinical Precautions: Renal: CRITICAL BACLOFEN RENAL WARNING: Baclofen is 85% excreted unchanged by the kidney — CONTRAINDICATED in eGFR <30 mL/min and dialysis (even 1–2 tablets of Baclofen 10 mg in dialysis patients cause acute coma and respiratory arrest!). Tizanidine: Halve dose if CrCl <25 mL/min. Hepatic: Avoid Tizanidine in liver disease
8. Adverse Effects Profile
- Drowsiness/sedation (up to 40–50%), dizziness, muscular weakness, dry mouth & hypotension (Tizanidine)
- Baclofen neurotoxicity/encephalopathy and coma in CKD (85% renally excreted unchanged!), severe hypotension & bradycardia (Tizanidine), drug-induced hepatitis (Tizanidine), rebound hypertension on abrupt Tizanidine withdrawal
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL CONTRAINDICATED TIZANIDINE INTERACTION: Ciprofloxacin and Fluvoxamine (potent CYP1A2 inhibitors) increase Tizanidine AUC by 10- to 33-fold, causing profound hypotension, bradycardia, and coma — NEVER co-prescribe! Oral contraceptives also increase Tizanidine levels 3-fold
- Additive CNS depression with Alcohol, Opioids, Benzodiazepines, and Pregabalin
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: COUNTER CHECKS: (1) Never dispense Baclofen (Liofen) to a patient with severe kidney failure or on dialysis; (2) Never stop chronic Liofen suddenly; (3) Never combine Tizanidine (Sirdalud) with Ciprofloxacin (Ciplox)!
- Meal & Clock Timing Instruction: Take Baclofen WITH food or milk to prevent nausea; take Tizanidine consistently either always with or always without food (Three times daily (or largest dose at bedtime for nocturnal flexor spasms))
- Missed Dose Protocol: Take as soon as remembered unless close to next dose; never allow chronic Baclofen stock to run out
- Geriatric Dispensing Pearl: Avoid as routine musculoskeletal relaxants in older adults (AGS Beers 2023); if Baclofen is required for neurological spasticity, verify eGFR >=30 mL/min and start at 5 mg OD–BD
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Baclofen Tablets: 5 mg, 10 mg, 20 mg; XL Capsules: 10 mg, 20 mg, 30 mg. Tizanidine Tablets: 2 mg, 4 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 07 [7.26] (p. 91)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [7.13]-C45 Chlorzoxazone — Centrally Acting Skeletal Muscle Relaxants & Antispasticity Agent
- [7.14]-C46 Meloxicam — Long-Half-Life Oxicam NSAIDs — Non-Selective & Preferential COX-2
- [7.16]-CMP47 Dicyclomine Hydrochloride IP & Hyoscine Butylbromide IP — Anthranilic Acid (Fenamate) COX-1 / COX-2 Inhibitor & Prostagland
- [7.20]-C48 Fentanyl Citrate — Pure Mu-Opioid Receptor Agonists — Narcotic Analgesics (NDPS Act
